Abstract
Abstract
Introduction
Immediately after Pfizer announced encouraging effectiveness and safety results from their COVID-19 vaccine clinical trials in 5- to 11-year-old children, this study aimed to assess parents’ perceptions and intention to vaccinate their 5-11-year-old children and to determine socio-demographic, health-related, behavioral factors, as well as the role of incentives.
Methods
A cross-sectional online survey of parents of children between 5 and 11 years of age among the Jewish population in Israel (n = 1,012). The survey was carried out between September 23 and October 4, 2021, at a critical time, immediately after Pfizer’s announcement. Two multivariate regressions were performed to determine predictors of parents’ intention to vaccinate their 5-11-year-old children against COVID-19.
Results
Overall, 57% of the participants reported that they intend to vaccinate their 5-11-year-old children against COVID-19 in the winter of 2022. 27% noted that they would vaccinate their 5-11-year-old children immediately; 26% within three months; and 24% within more than three months. Perceived susceptibility, benefits, barriers and cues to action, as well as two incentives - vaccine availability and receiving a “Green Pass” - were all significant predictors. However, Incentives such as monetary rewards or monetary penalties did not increase the probability of parents’ intention to vaccinate their children. Parental concerns centered around the safety of the vaccine, fear of severe side effects, and fear that clinical trials and the authorization process were carried out too quickly.
Conclusion
This study provides data on the role of incentives in vaccinating 5-11-year-old children, how soon they intend to do so, and the predictors of those intentions, which is essential knowledge for health policy makers planning vaccination campaigns.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference35 articles.
1. Children. and COVID-19: State-Level Data Report, (n.d.). http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ (accessed October 10, 2021).
2. Preliminary Evidence on Long COVID in children | medRxiv., (n.d.). https://www.medrxiv.org/content/https://doi.org/10.1101/2021.01.23.21250375v1.full (accessed October 23, 2021).
3. Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Curr Opin Pediatr. 2021;33:144–51. https://doi.org/10.1097/MOP.0000000000000978.
4. Dooling K. Use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥ 16 years: recommendations of the Advisory Committee on Immunization Practices — United States, September 2021, MMWR Morb. Mortal Wkly Rep. 2021;70. https://doi.org/10.15585/mmwr.mm7038e2.
5. O. of the Commissioner, Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic, FDA. (2021). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use (accessed September 29, 2021).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献